Health
Genentech Announces FDA Approval of Xofluza for the Prevention of Influenza Following Contact With an Infected Person – Manchestertimes
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Nov 23, 2020–
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Nov 23, 2020–
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for Xofluza ® (baloxavir marboxil) as a treatment to prevent influenza in people 12 years of age and older following contact with someone with influenza (known as post-exposure prophylaxis). Xofluza is the first single-dose influenza medicine approved…
-
General21 hours agoCampers evacuated, residents on alert as Moreton Island bushfire intensifies
-
General19 hours agoHundreds attend justice march for Kaiden Morgan-Johnston in Morwell
-
Noosa News22 hours agoATO investigator found to have lied in fraud case
-
Noosa News20 hours agoHow Roosters star Eliza Lopamaua found her way to NRLW